[1]
Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical microbiology reviews. 2018 Oct:31(4):. doi: 10.1128/CMR.00021-18. Epub 2018 Jul 18
[PubMed PMID: 30021818]
[2]
Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. Nature reviews. Disease primers. 2016 Oct 27:2():16076. doi: 10.1038/nrdp.2016.76. Epub 2016 Oct 27
[PubMed PMID: 27784885]
[3]
Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. The New England journal of medicine. 2004 May 13:350(20):2060-7
[PubMed PMID: 15141044]
[4]
García-Basteiro AL, Brew J, Williams B, Borgdorff M, Cobelens F. What is the true tuberculosis mortality burden? Differences in estimates by the World Health Organization and the Global Burden of Disease study. International journal of epidemiology. 2018 Oct 1:47(5):1549-1560. doi: 10.1093/ije/dyy144. Epub
[PubMed PMID: 30010785]
[5]
Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS medicine. 2016 Oct:13(10):e1002152. doi: 10.1371/journal.pmed.1002152. Epub 2016 Oct 25
[PubMed PMID: 27780211]
[6]
Churchyard G, Kim P, Shah NS, Rustomjee R, Gandhi N, Mathema B, Dowdy D, Kasmar A, Cardenas V. What We Know About Tuberculosis Transmission: An Overview. The Journal of infectious diseases. 2017 Nov 3:216(suppl_6):S629-S635. doi: 10.1093/infdis/jix362. Epub
[PubMed PMID: 29112747]
Level 3 (low-level) evidence
[7]
Menzies D. Screening for Latent Tuberculosis Infection. JAMA network open. 2023 May 1:6(5):e2312114. doi: 10.1001/jamanetworkopen.2023.12114. Epub 2023 May 1
[PubMed PMID: 37129898]
[8]
Starke JR. Tuberculin Skin Test Versus the Interferon-γ Release Assays: Out With the Old, In With the New. Pediatrics. 2020 Jan:145(1):. pii: e20193021. doi: 10.1542/peds.2019-3021. Epub
[PubMed PMID: 31892521]
[9]
Kestler B, Tyler SK. Latent tuberculosis testing through the ages: the search for a sleeping killer. American journal of physiology. Lung cellular and molecular physiology. 2022 Mar 1:322(3):L412-L419. doi: 10.1152/ajplung.00217.2021. Epub 2022 Feb 16
[PubMed PMID: 35170334]
[10]
Bouwman JJ, Thijsen SF, Bossink AW. Improving the timeframe between blood collection and interferon gamma release assay using T-Cell Xtend®. The Journal of infection. 2012 Feb:64(2):197-203. doi: 10.1016/j.jinf.2011.10.017. Epub 2011 Nov 18
[PubMed PMID: 22120115]
[11]
Wang SH, Powell DA, Nagaraja HN, Morris JD, Schlesinger LS, Turner J. Evaluation of a modified interferon-gamma release assay for the diagnosis of latent tuberculosis infection in adult and paediatric populations that enables delayed processing. Scandinavian journal of infectious diseases. 2010 Dec:42(11-12):845-50. doi: 10.3109/00365548.2010.498021. Epub 2010 Jul 7
[PubMed PMID: 20608764]
[12]
Furin J. Advances in the diagnosis, treatment, and prevention of tuberculosis in children. Expert review of respiratory medicine. 2019 Mar:13(3):301-311. doi: 10.1080/17476348.2019.1569518. Epub 2019 Jan 22
[PubMed PMID: 30648437]
Level 3 (low-level) evidence
[13]
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Jan 15:64(2):111-115. doi: 10.1093/cid/ciw778. Epub
[PubMed PMID: 28052967]
Level 1 (high-level) evidence
[14]
Pennie RA. Mantoux tests. Performing, interpreting, and acting upon them. Canadian family physician Medecin de famille canadien. 1995 Jun:41():1025-9
[PubMed PMID: 7780314]
[15]
Shafeque A, Bigio J, Hogan CA, Pai M, Banaei N. Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence? Journal of clinical microbiology. 2020 Aug 24:58(9):. doi: 10.1128/JCM.01950-19. Epub 2020 Aug 24
[PubMed PMID: 32493779]
[16]
Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2022 Nov:124 Suppl 1():S12-S19. doi: 10.1016/j.ijid.2022.02.047. Epub 2022 Mar 5
[PubMed PMID: 35257904]
[17]
Zhou G, Luo Q, Luo S, Chen H, Cai S, Guo X, He J, Xia Y, Li H, Zhou Y, Zhang Y, Song C. Indeterminate results of interferon gamma release assays in the screening of latent tuberculosis infection: a systematic review and meta-analysis. Frontiers in immunology. 2023:14():1170579. doi: 10.3389/fimmu.2023.1170579. Epub 2023 May 15
[PubMed PMID: 37256138]
Level 1 (high-level) evidence
[18]
Ma Y, Li R, Shen J, He L, Li Y, Zhang N, Wu Q, Zhang J, Zheng J, Wang X. Clinical effect of T-SPOT.TB test for the diagnosis of tuberculosis. BMC infectious diseases. 2019 Nov 21:19(1):993. doi: 10.1186/s12879-019-4597-8. Epub 2019 Nov 21
[PubMed PMID: 31752713]
[19]
King TC, Upfal M, Gottlieb A, Adamo P, Bernacki E, Kadlecek CP, Jones JG, Humphrey-Carothers F, Rielly AF, Drewry P, Murray K, DeWitt M, Matsubara J, O'Dea L, Balser J, Wrighton-Smith P. T-SPOT.TB Interferon-γ Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals. American journal of respiratory and critical care medicine. 2015 Aug 1:192(3):367-73. doi: 10.1164/rccm.201501-0199OC. Epub
[PubMed PMID: 26017193]
[20]
Wattal C, Raveendran R. Newer Diagnostic Tests and their Application in Pediatric TB. Indian journal of pediatrics. 2019 May:86(5):441-447. doi: 10.1007/s12098-018-2811-0. Epub 2019 Jan 10
[PubMed PMID: 30628039]
[21]
Ortiz-Brizuela E, Apriani L, Mukherjee T, Lachapelle-Chisholm S, Miedy M, Lan Z, Korobitsyn A, Ismail N, Menzies D. Assessing the Diagnostic Performance of New Commercial Interferon-γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Jun 8:76(11):1989-1999. doi: 10.1093/cid/ciad030. Epub
[PubMed PMID: 36688489]
Level 1 (high-level) evidence
[22]
. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 1995 Sep 8:44(RR-11):19-34
[PubMed PMID: 7565540]
[23]
. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1: prevention. 2020:():
[PubMed PMID: 32186832]
[24]
Shah MI, Mishra S, Yadav VK, Chauhan A, Sarkar M, Sharma SK, Rout C. Ziehl-Neelsen sputum smear microscopy image database: a resource to facilitate automated bacilli detection for tuberculosis diagnosis. Journal of medical imaging (Bellingham, Wash.). 2017 Apr:4(2):027503. doi: 10.1117/1.JMI.4.2.027503. Epub 2017 Jun 30
[PubMed PMID: 28680911]
[25]
Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, Banaei N. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clinical microbiology reviews. 2014 Jan:27(1):3-20. doi: 10.1128/CMR.00034-13. Epub
[PubMed PMID: 24396134]
[26]
Gundogdu Z, Aydogan M, Arisoy ES, Gokalp AS. Effect of number of BCG vaccination on tuberculin induration size. Journal of paediatrics and child health. 2007 Jun:43(6):476-9
[PubMed PMID: 17535179]
[27]
Bugiani M, Borraccino A, Migliore E, Carosso A, Piccioni P, Cavallero M, Caria E, Salamina G, Arossa W. Tuberculin reactivity in adult BCG-vaccinated subjects: a cross-sectional study. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2003 Apr:7(4):320-6
[PubMed PMID: 12729336]
Level 2 (mid-level) evidence
[28]
Santos JA, Duarte R, Nunes C. Host factors associated to false negative and indeterminate results in an interferon-γ release assay in patients with active tuberculosis. Pulmonology. 2020 Nov-Dec:26(6):353-362. doi: 10.1016/j.pulmoe.2019.11.001. Epub 2019 Dec 13
[PubMed PMID: 31843341]
[29]
. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2000 Jun 9:49(RR-6):1-51
[PubMed PMID: 10881762]
[30]
Al Mazrou AM. Booster effect of two-step tuberculin skin testing among hospital employees from areas with a high prevalence of tuberculosis. Infection control and hospital epidemiology. 2004 Dec:25(12):1117-20
[PubMed PMID: 15636304]
[31]
Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. American journal of respiratory and critical care medicine. 1999 Jan:159(1):15-21
[PubMed PMID: 9872812]
[32]
Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, Weber RP, Jonas DE. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016 Sep 6:316(9):970-83. doi: 10.1001/jama.2016.10357. Epub
[PubMed PMID: 27599332]
Level 1 (high-level) evidence
[33]
Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, Angelberger S, Novacek G, Mikulits A, Vogelsang H, Reinisch W. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. European journal of clinical investigation. 2011 Oct:41(10):1071-6. doi: 10.1111/j.1365-2362.2011.02502.x. Epub 2011 Mar 17
[PubMed PMID: 21413978]
[34]
Brown J, Kumar K, Reading J, Harvey J, Murthy S, Capocci S, Hopkins S, Seneviratne S, Cropley I, Lipman M. Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. The European respiratory journal. 2017 Oct:50(4):. pii: 1701267. doi: 10.1183/13993003.01267-2017. Epub 2017 Oct 26
[PubMed PMID: 29074546]
[35]
Sharninghausen JC, Shapiro AE, Koelle DM, Kim HN. Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection. Open forum infectious diseases. 2018 Aug:5(8):ofy184. doi: 10.1093/ofid/ofy184. Epub 2018 Jul 27
[PubMed PMID: 30151410]
[36]
Oh CE, Ortiz-Brizuela E, Bastos ML, Menzies D. Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Sep 7:73(5):e1116-e1125. doi: 10.1093/cid/ciaa1822. Epub
[PubMed PMID: 33289038]
Level 1 (high-level) evidence
[37]
Christopher DJ, Shankar D, Datey A, Zwerling A, Pai M. Safety of the two-step tuberculin skin test in Indian health care workers. International journal of mycobacteriology. 2014 Dec:3(4):247-51. doi: 10.1016/j.ijmyco.2014.10.004. Epub 2014 Oct 23
[PubMed PMID: 26786623]
[38]
Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC infectious diseases. 2006 Mar 15:6():47
[PubMed PMID: 16539718]
Level 2 (mid-level) evidence